Cargando…
Alternative lengthening of telomeres: from molecular mechanisms to therapeutic outlooks
To escape replicative senescence, cancer cells have to overcome telomere attrition during DNA replication. Most of cancers rely on telomerase to extend and maintain telomeres, but 4–11% of cancers use a homologous recombination-based pathway called alternative lengthening of telomeres (ALT). ALT is...
Autores principales: | Zhang, Jia-Min, Zou, Lee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063710/ https://www.ncbi.nlm.nih.gov/pubmed/32175073 http://dx.doi.org/10.1186/s13578-020-00391-6 |
Ejemplares similares
-
The Molecular Mechanisms and Therapeutic Prospects of Alternative Lengthening of Telomeres (ALT)
por: Sohn, Eric J., et al.
Publicado: (2023) -
Alternative Lengthening of Telomeres and Mediated Telomere Synthesis
por: Hou, Kailong, et al.
Publicado: (2022) -
The Role of Alternative Lengthening of Telomeres Mechanism in Cancer: Translational and Therapeutic Implications
por: Recagni, Marta, et al.
Publicado: (2020) -
Alternative Lengthening of Telomeres and Chromatin Status
por: Udroiu, Ion, et al.
Publicado: (2019) -
Potential clinical treatment prospects behind the molecular mechanism of alternative lengthening of telomeres (ALT)
por: Sun, Haolu, et al.
Publicado: (2023)